Consistency was the dominant impression of Roche’s annual analyst presentation in conjunction with the American Society of Clinical Oncology annual meeting, as the company continued to progress its plans to build a broad network of new agents around the flagship cancer immunotherapy Tecentriq (atezolizumab) with an eye toward precision combination therapy.
For Roche Immuno-Oncology, It’s Steady As She Goes
Roche’s oncology R&D juggernaut gains momentum with surge of combination trials around cancer immunotherapy, illustrated in an animated chart. But the company is keeping its focus on systematically building a base of randomized clinical data to back up efficacy signals for PD-L1 inhibitor Tecentriq
